HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Victoria Johnson

Victoria Johnson, Assistant Editor for GeneTherapyLive, joined the MJH Life Sciences team in October 2020, originally writing for NeurologyLive. Follow her on Twitter @VictoriaJNeuro or email her at vjohnson@genetherapylive.com​.


Passage Bio Doses First Patient in Frontotemporal Dementia Gene Therapy Trial

August 16, 2022

The AAV1 gene therapy, PBFT02, is being assessed in a phase 1/2 trial called upliFT-D (NCT04747431), which is planned to take place over the course of 24 months in patients with frontotemporal dementia with granulin mutations.